Cushing Syndrome Pipeline, Clinical Trials, and Key Companies|Companies – Corcept Therapeutics, Crinetics Pharmaceuticals, Cyclacel Pharmaceuticals, Sparrow Pharmaceuticals, Stero Therapeutics,
(United States, Nevada, Las Vegas), DelveInsight’s “Cushing’s Syndrome – Pipeline Insight, 2023” report provides comprehensive insights about 6+ companies and 8+ pipeline drugs in Cushing’s Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Cushing Syndrome Pipeline Report
-
Over 6+ companies and 8+ pipeline drugs in Cushing Syndrome are in various stages of development, and their anticipated acceptance in the Cushing Syndrome market would significantly increase market revenue.
-
Leading Cushing Syndrome companies developing novel drug candidates to improve the Cushing Syndrome treatment landscape include Corcept Therapeutics, Crinetics Pharmaceuticals, Cyclacel Pharmaceuticals, Sparrow Pharmaceuticals, Stero Therapeutics, OMass Therapeutics
-
Promising Cushing Syndrome pipeline therapies in various stages of development include Relacorilant, SPI-62, and many others.
Cushing Syndrome Overview
Cushing syndrome is caused by prolonged exposure to high circulating levels of cortisol. The most common cause of cushingoid features is iatrogenic corticosteroid use, while some herbal preparations can also increase circulating corticosteroid levels leading to Cushing syndrome. Cushing syndrome can be interchangeably called hypercortisolism. ACTH-dependent cortisol excess due to a pituitary adenoma is called Cushing disease, and it is responsible for 80% of endogenous Cushing syndrome. There are two main etiologies of Cushing syndrome: endogenous hypercortisolism and exogenous hypercortisolism. Exogenous hypercortisolism, the most common cause of Cushing syndrome, is mostly iatrogenic and results from the prolonged use of glucocorticoids.
Cushing Syndrome Pipeline Analysis: Drug Profile
Relacorilant: Corcept Therapeutics
Relacorilant is a non-steroidal, selective modulator of the glucocorticoid receptor, the receptor for cortisol which is activated when cortisol levels are high. Relacorilant does not bind to the body’s other hormone receptors. Corcept is studying relacorilant as a potential treatment for a variety of serious disorders, including Cushing’s syndrome and advanced adrenal, ovarian and pancreatic cancer. Relacorilant is proprietary to Corcept and is protected by composition of matter and method of use patents. Relacorilant has received orphan drug designation in the United States for the treatment of Cushing’s syndrome and pancreatic cancer. A Phase III Study Evaluating the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome is currently ongoing.
Discover more about the emerging Cushing Syndrome drugs @ Cushing Syndrome Disease Treatment Drugs
Cushing Syndrome Pipeline Therapies and Key Companies
-
Relacorilant: Corcept Therapeutics
-
SPI-62: Sparrow Pharmaceuticals
And many others
Cushing Syndrome PipelineTherapeutics Assessment
This segment of the report provides insights about the different Cushing Syndrome drugs segregated based on the following parameters that define the scope of the report, such as:
Major Players in Cushing Syndrome
There are approx. 6+ key companies developing therapies for Cushing Syndrome. The companies which have their Cushing Syndrome drug candidates in the most advanced stage, i.e. phase III include Corcept Therapeutics.
Phases
DelveInsight’s Report covers around 8+ products under different phases of clinical development like
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I) along with the details of
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Route of Administration
Cushing Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Oral
-
Parenteral
-
Intravenous
-
Subcutaneous
-
Topical.
Molecule Type
Products have been categorized under various Molecule types such as
-
Monoclonal Antibody
-
Peptides
-
Polymer
-
Small molecule
-
Gene therapy
Scope of the Cushing Syndrome Pipeline Report
-
Coverage: Global
-
Key Cushing Syndrome Companies: Corcept Therapeutics, Crinetics Pharmaceuticals, Cyclacel Pharmaceuticals, Sparrow Pharmaceuticals, Stereo Therapeutics, OMass Therapeutics, and others
-
Key Cushing Syndrome Pipeline Therapies: Relacorilant, SPI-62, and others
Table of Contents
1. Cushing Syndrome Introduction
2. Cushing Syndrome Executive Summary
3. Cushing Syndrome Overview
4. Cushing Syndrome Pipeline Therapeutics
5. Cushing Syndrome Late-Stage Products (Phase III)
6. Cushing Syndrome Mid-Stage Products (Phase II)
7. Cushing Syndrome Early Stage Products (Phase I/II)
8. Cushing Syndrome Preclinical Stage Products
9. Cushing Syndrome Discovery Stage Products
10. Cushing Syndrome Therapeutic Assessment
11. Cushing Syndrome Inactive Products
12. Cushing SyndromeCollaborations Assessment- Licensing / Partnering / Funding
13. Cushing Syndrome Unmet Needs
14. Cushing Syndrome Market Drivers and Barriers
15. Appendix
16. About DelveInsight
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
